Drugs / LAT010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06277219 | Jun 2024 → Dec 2026 expected | neoplasm | Latticon Antibody Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAT010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06277219 ↗ |
| Action | Activate | “Its exceptional selectivity in activating CD8+ T cells and NK cells may confer the clinical benefits of IL-2” NCT06277219 ↗ |
| Modality | Protein / enzyme biologic | “LAT010 is a human IL-2 based immunocytokine” NCT06277219 ↗ |
| Route | Intravenous | “patients will receive an IV injection of LAT010 at the assigned dose once weekly” NCT06277219 ↗ |